
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight is a commercial-stage medical technology company with a positive outlook due to its collaboration with ALC for light adjustable versions of certain ALC presbyopia correcting IOLs, which will provide up to $200 million in development and regulatory milestone payments and a potential 30% royalty on future sales. Additionally, the company's revenue beat consensus in 2Q26 and management reiterated its 2026 revenue guidance, giving confidence in potential growth. However, there are risks to consider, such as limited adoption and potential competition in the IOL market. Based on these factors, a Buy rating is maintained with a 12-month price target of $11-13.
Bears say
RxSight is facing several risks due to its limited adoption of an incremental capital equipment, disappointing commercial execution, increased competition in the intraocular lens market, and the potential for a dilutive financing round. Despite management's reassurance and recent revenue beat, the company's future success is heavily reliant on a steady recovery and re-engagement initiatives. Additionally, the company's high valuation multiples make it vulnerable to any potential setbacks, with a worst-case scenario of a $7 per share price estimate based on an EV/sales multiple of 0.5x the 2027 sales estimate.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares